Vertex Pharmaceuticals
-
Vertex expands partnership with MNGHA to advance gene therapy care in Saudi Arabia
The announcement was made at the Riyadh Global Medical Biotechnology Summit (RGMBS), building on a collaboration established after Saudi Arabia’s first gene therapy infusion in 2024.
-
Vertex completes US$10B Crinetics acquisition to expand endocrine disease portfolio
The acquisition adds rare endocrine diseases as a new growth area alongside Vertex’s existing focus on cystic fibrosis, hematology, acute pain and renal disease.
-
Vertex expands autoimmune pipeline with US$28M multispecific antibody collaboration with AbCellera
AbCellera will oversee discovery and early-stage development activities, while Vertex will finance all research and development costs.
-
Vertex Casgevy wins landmark FDA approval for toddlers with SCD and TDT
The expanded label is expected to make about 5,500 additional children in the United States eligible for treatment.
-
Abu Dhabi’s Yas Clinic successfully delivers landmark CASGEVY gene treatment
This cutting-edge approach represents a major advancement in how doctors can treat genetic diseases by directly modifying the faulty genes responsible for these conditions.